Exploring the link between imaging and tumor environment in lung cancer
Assessment the Association of Imaging and Tumor Microenvironment in Lung Cancer With Radiogenomics
This study looks at how chest scans can help us understand the tumor environment and outcomes for people with lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06500312 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to investigate how imaging data correlates with the tumor microenvironment and prognosis in lung cancer patients. Conducted at Wuhan Union Hospital, it will involve patients treated for lung cancer from July 2024 to July 2027, who have undergone at least one chest CT scan and have a confirmed diagnosis through tissue biopsy. The study will analyze the relationship between imaging characteristics and clinical outcomes to enhance understanding of lung cancer progression.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who have been treated for lung cancer at Wuhan Union Hospital and have undergone a chest CT scan.
Not a fit: Patients with poor image quality, incomplete clinical data, or other primary malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools and personalized treatment strategies for lung cancer patients.
How similar studies have performed: While the specific approach of radiogenomics in lung cancer is still emerging, similar studies have shown promise in correlating imaging features with tumor biology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2024 to July 2027; 2. Aged \> 18 years old; 3. At least one chest CT scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion Criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than lung cancer; 4. Unclear pathological diagnosis。
Where this trial is running
Wuhan, Hubei
- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Lian Yang
- Email: yanglian@hust.edu.cn
- Phone: 18986273791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.